Trial
NCT05116917
Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Herlev Hospital
Collaborators
—
Condition
Pancreatic Cancer
Intervention
Nivolumab
Why stopped
Based on the precpecified interim analysis the predictive probability was below 10% for the prespecified endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-28